Roads to remission: evolving treatment concepts in type 2 inflammatory diseases
Summary: Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537024006291 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553800383430656 |
|---|---|
| author | Marek Lommatzsch Katharina Blumchen Lisa A. Beck Jean Bousquet Guy G. Brusselle Wytske J. Fokkens Eckard Hamelmann Susanne Lau Hagen Ott Oliver Pfaar Hugh A. Sampson Josef S. Smolen Christian Taube Ingo H. Tarner Martin Wagenmann Thomas Werfel Margitta Worm Harald Renz |
| author_facet | Marek Lommatzsch Katharina Blumchen Lisa A. Beck Jean Bousquet Guy G. Brusselle Wytske J. Fokkens Eckard Hamelmann Susanne Lau Hagen Ott Oliver Pfaar Hugh A. Sampson Josef S. Smolen Christian Taube Ingo H. Tarner Martin Wagenmann Thomas Werfel Margitta Worm Harald Renz |
| author_sort | Marek Lommatzsch |
| collection | DOAJ |
| description | Summary: Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs. Funding: None. |
| format | Article |
| id | doaj-art-28552a17fdfb4aa7bd83f134c2224b10 |
| institution | Kabale University |
| issn | 2589-5370 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj-art-28552a17fdfb4aa7bd83f134c2224b102025-01-09T06:14:26ZengElsevierEClinicalMedicine2589-53702025-02-0180103050Roads to remission: evolving treatment concepts in type 2 inflammatory diseasesMarek Lommatzsch0Katharina Blumchen1Lisa A. Beck2Jean Bousquet3Guy G. Brusselle4Wytske J. Fokkens5Eckard Hamelmann6Susanne Lau7Hagen Ott8Oliver Pfaar9Hugh A. Sampson10Josef S. Smolen11Christian Taube12Ingo H. Tarner13Martin Wagenmann14Thomas Werfel15Margitta Worm16Harald Renz17Department of Pneumology and Intensive Care Medicine, University of Rostock, GermanyDepartment of Pediatrics, Goethe University, Frankfurt, GermanyDepartment of Dermatology, University of Rochester, Rochester, USAInstitute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, GermanyDepartment of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumDepartment of Otorhinolaryngology, University Medical Centers (UMC), Amsterdam, the NetherlandsDepartment of Pediatrics, University of Bielefeld, Bielefeld, GermanyDepartment of Pediatrics, Charité, University Medicine Berlin, Berlin, GermanyDepartment of Pediatric Dermatology and Allergology, Children's Hospital Auf der Bult, Hannover, GermanyDepartment of Ear, Nose and Throat Medicine, Philipps University Marburg, Marburg, GermanyJaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, USADepartment of Rheumatology, University of Vienna, Vienna, AustriaDepartment of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen, GermanyDepartment of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Kerckhoff-Klinik, Bad Nauheim, GermanyDepartment of Ear, Nose and Throat Medicine, Heinrich Heine University of Düsseldorf, Düsseldorf, GermanyDepartment of Dermatology and Allergology, University of Hannover, Hannover, GermanyDepartment of Dermatology, Charité, University Medicine Berlin, Berlin, GermanyInstitute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Marburg, Germany; Corresponding author. Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Baldingerstrasse, 35043, Marburg, Germany.Summary: Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs. Funding: None.http://www.sciencedirect.com/science/article/pii/S2589537024006291RemissionDisease modificationType 2 inflammation |
| spellingShingle | Marek Lommatzsch Katharina Blumchen Lisa A. Beck Jean Bousquet Guy G. Brusselle Wytske J. Fokkens Eckard Hamelmann Susanne Lau Hagen Ott Oliver Pfaar Hugh A. Sampson Josef S. Smolen Christian Taube Ingo H. Tarner Martin Wagenmann Thomas Werfel Margitta Worm Harald Renz Roads to remission: evolving treatment concepts in type 2 inflammatory diseases EClinicalMedicine Remission Disease modification Type 2 inflammation |
| title | Roads to remission: evolving treatment concepts in type 2 inflammatory diseases |
| title_full | Roads to remission: evolving treatment concepts in type 2 inflammatory diseases |
| title_fullStr | Roads to remission: evolving treatment concepts in type 2 inflammatory diseases |
| title_full_unstemmed | Roads to remission: evolving treatment concepts in type 2 inflammatory diseases |
| title_short | Roads to remission: evolving treatment concepts in type 2 inflammatory diseases |
| title_sort | roads to remission evolving treatment concepts in type 2 inflammatory diseases |
| topic | Remission Disease modification Type 2 inflammation |
| url | http://www.sciencedirect.com/science/article/pii/S2589537024006291 |
| work_keys_str_mv | AT mareklommatzsch roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT katharinablumchen roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT lisaabeck roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT jeanbousquet roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT guygbrusselle roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT wytskejfokkens roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT eckardhamelmann roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT susannelau roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT hagenott roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT oliverpfaar roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT hughasampson roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT josefssmolen roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT christiantaube roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT ingohtarner roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT martinwagenmann roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT thomaswerfel roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT margittaworm roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases AT haraldrenz roadstoremissionevolvingtreatmentconceptsintype2inflammatorydiseases |